F&P Healthcare's valuation is stretched – analyst
The healthcare company is battling hard with a rival.
Hot Topic
Hawke’s Bay
An analyst is concerned Fisher & Paykel Healthcare’s valuation is stretched, as the company battles intellectual property with a rival.
First NZ Capital analyst Tristan Joll has moved his rating on the stock from neutral to underperform. He says while quality remains, valuation is stretched – it
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Tue, 17 Oct 2017
Tue, 17 Oct 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
F&P Healthcare's valuation is stretched – analyst
70854